Dual ABCB4/ABCB11 modulation shows promise in cholestatic disease models

June 8, 2026

Researchers from Rectify Pharmaceuticals Inc. presented preclinical efficacy data on RTY-406, a novel dual-acting ABCB4/MDR3 and ABCB11/BSEP modulator, in animal models of primary sclerosing cholangitis.

BioWorld Science Conferences EASL Gastrointestinal

Today's news in brief

BioWorld

BioWorld briefs for July 13, 2026.

FENS 2026: Next-gen biologics take on brain disease

BioWorld

Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...

Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy

BioWorld

News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...

Modius Spero wearable neuromodulation device

Neurovalens granted FDA approval for PTSD therapy for US veterans

BioWorld

Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...

NRF2 activators reported in Vailima Peninsula patent

BioWorld Science

Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...